Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
August 10, 2023 06:30 ET
|
Verve Therapeutics
heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and...
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
August 03, 2023 06:30 ET
|
Verve Therapeutics
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
June 15, 2023 06:30 ET
|
Verve Therapeutics
Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and...
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 01, 2023 06:30 ET
|
Verve Therapeutics
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
May 23, 2023 06:30 ET
|
Verve Therapeutics
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
May 15, 2023 06:30 ET
|
Verve Therapeutics
heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical...
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
May 09, 2023 06:30 ET
|
Verve Therapeutics
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023 06:30 ET
|
Verve Therapeutics
BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
March 03, 2023 06:30 ET
|
Verve Therapeutics
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data...
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023 06:30 ET
|
Verve Therapeutics
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with...